<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261153</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A03112-55</org_study_id>
    <nct_id>NCT04261153</nct_id>
  </id_info>
  <brief_title>Use of Cognitive Stimulation Software for Patients Over the Age of 70 Followed for Breast Cancer: COG-TAB-AGE Feasibility Study</brief_title>
  <acronym>COG-TAB-AGE</acronym>
  <official_title>Use of Cognitive Stimulation Software for Patients Over the Age of 70 Followed for Breast Cancer: COG-TAB-AGE Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Numerous studies have shown the impact of anti-cancer treatments on cognition and more
      particularly that of chemotherapy. Elderly patients also seem to be at higher risk of
      developing cognitive impairment. These disorders can have a particularly negative impact in
      this population, in particular by having repercussions on the observance of oral treatments
      or even on autonomy. However, investigators still have little data concerning the management
      of cognitive disorders induced by oncology treatments, particularly in the elderly patient.
      It is therefore necessary to offer care adapted to this population which will allow the
      reduction of the sequelae induced by cancer treatments and the improvement of the quality of
      life of elderly patients.Although there are no preventive measures yet, recent studies of
      young women being treated for breast cancer with a cognitive complaint have shown a
      beneficial effect of cognitive stimulation on these cognitive disorders. Stimulation programs
      of this type have been developed in electronic format. However, to date, they have not been
      the subject of specific studies with elderly patients in whom the use of computer interface
      can be an obstacle.Sponsor propose to set up a study aimed at evaluating the feasibility of
      using cognitive stimulation software on tablets with elderly patients.The HAPPYNeuron®
      software, developed by a French team of neurologists, speech-language pathologists and
      psychiatrists, offers exercises to be performed online to stimulate the cognitive functions
      most impaired by oncological treatments (memory, attention, executive functions and speed of
      treatment).For this feasibility study, the sponsor plan to include 50 patients aged 70 and
      over to have them test the acceptance of cognitive stimulation by this software with a tablet
      interface.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptance rate</measure>
    <time_frame>between inclusion to 1 week</time_frame>
    <description>Satisfaction questionnary (Patient satisfaction questionnary; minimum 1 to maximum 5; 8 questions)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>cognitive stimulation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive stimulation</intervention_name>
    <description>3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days</description>
    <arm_group_label>cognitive stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with breast cancer, aged 70 and over,

          -  During treatment with chemotherapy combined or not with targeted therapy,

          -  Whatever the stage of the disease,

          -  Hospitalized in week hospital, in traditional hospitalization for an intercurrent
             episode or in day hospitalization

          -  Absence of major cognitive impairment preventing cognitive tests (compliance with the
             MoCA score threshold based on the patient's age and educational level according to
             GRECOGVASC standards),

          -  Patient with education level 3 &quot;end of primary education&quot; minimum (Barbizet scale),

          -  Mastery of the French language,

          -  Patient who signed the consent to participate in the study.

        Exclusion Criteria:

          -  Hospitalization for neurological reasons (e.g. confusion), or psychiatric,

          -  Documented brain metastases,

          -  History of brain radiation therapy,

          -  Progressive psychiatric pathology or known dementia,

          -  Abuse of alcohol or drug use,

          -  Severe visual and / or hearing loss,

          -  Patient's refusal to participate,

          -  Patient deprived of liberty or under guardianship.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mélanie DOS SANTOS, MD</last_name>
    <phone>+ 33 2 31 45 50 02</phone>
    <email>m.dossantos@baclesse.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Michel GRELLARD</last_name>
    <phone>+ 33 2 31 45 50 02</phone>
    <email>jm.grellard@baclesse.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie DOS SANTOS, MD</last_name>
      <phone>+33 2 31 45 50 02</phone>
      <email>m.dossantos@baclesse.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Michel Grellard</last_name>
      <phone>+33 2 31 45 50 02</phone>
      <email>jm.grellard@baclesse.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Mélanie DOS SANTOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle LEVY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George EMILE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Djelila ALLOUACHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien GEFFRELOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine SEGURA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey FAVEYRIAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier RIGAL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier RIGAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina ALEXANDRU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laetitia AUGUSTO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florian CLATOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederic DI FIORE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maxime FONTANILLES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole FRONVILLE-VARNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie GOUERANT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile GUILLEMET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marianne LEHEURTEUR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristian MOLDOVAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille PETRAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle TENNEVET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe THERY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

